• 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8

RHEACELL: Bringing Stem Cell Therapies to Patients

Orphan Drug Designations
  • allo-APZ2-EB (ABCB5+ MSCs) for epidermolysis bullosa (EMA, FDA)
  • LSC2 (ABCB5+ LSCs) for limbal stem cell deficiency (EMA)

Fast Track Designation
  • LSC2 (ABCB5+ LSCs) for limbal stem cell deficiency (FDA)

FDA Clinical Trial Approvals (in addition to European approvals)
  • International, multicentric trial of ABCB5+ MSCs to treat recessive dystrophic epidermolysis bullosa
  • International, multicentric trial of ABCB5+ LSCs to treat limbal stem cell deficiency

Building upon highly functional human skin-derived ABCB5-positive mesenchymal stem cells (MSCs) as a platform technology, RHEACELL develops advanced-therapy medicinal products to treat currently uncurable inflammatory and degenerative diseases. Further areas of research and development include ABCB5-positive limbal stem cells (LSCs) and immunotherapies against ABCB5-expressing cancers.

We make use of ABCB5-related U.S. and international patents assigned to Boston Children’s Hospital and/or Brigham and Women’s Hospital (Harvard Medical School, Boston, Massachusetts) that are exclusively licensed to RHEACELL and our parent company TICEBA. Co-inventor Markus H. Frank, M.D., Professor at Harvard Medical School, serves as a scientific advisor to RHEACELL.

For an overview of all clinical trials and study centers in Germany and worldwide go to Clinical Trials on the navigation bar.

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.